Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus CHILDREN S ALLEGRA HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus CHILDREN S ALLEGRA HIVES.
BENYLIN vs CHILDREN'S ALLEGRA HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Category C
Category C
Antihistamine
Antihistamine